XML 30 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Research and Development Expense for Major Programs
The following table sets forth significant research and development (“R&D”) expenses by program as regularly provided to the CODM (in thousands):

Three Months Ended 
September 30,		Nine Months Ended 
September 30,
2025202420252024
Birtamimab (NEOD001)
$7,136 $18,159 $52,483 $60,908 
PRX012
14,653 28,093 47,821 97,900 
PRX019
2,192 1,328 6,118 2,785 
Other R&D
4,957 3,143 13,844 10,754 
Total R&D
$28,938 $50,723 $120,266 $172,347